封面
市場調查報告書
商品編碼
2173136

Pegfilgrastim市場:全球市場預測,2026-2032年

Pegfilgrastim Market - Global Forecast 2026-2032

出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年,Pegfilgrastim市場將成長至 39.9 億美元,複合年成長率為 5.33%。

主要市場統計數據
基準年 2025 27.7億美元
預計年份:2026年 29.1億美元
預測年份 2032 39.9億美元
複合年成長率 (%) 5.33%

Pegfilgrastim:執行摘要與市場趨勢

Pegfilgrastim是一種長效顆粒細胞增生因子 CSF),用於縮短化療嗜中性白血球低下症減少症的持續時間,並降低適宜患者發生嗜中性白血球低下症減少症的機率。其臨床價值在於與短效Filgrastim相比,給藥頻率更低,從而提高治療依從性並減輕注射負擔。其使用通常取決於化療風險、患者特徵、治療目標、當地指南以及醫療保險報銷條件。

醫療保健服務正朝著嗜中性白血球低下症的方向發展。

目前的趨勢是基於風險的預防、標準化的支持性護理路徑以及對治療連續性的日益重視。醫院和腫瘤網路越來越重視化療的發展、劑量強度、不利事件監測和及時介入。生物相似藥的供應也影響採購和處方清單的決策,在臨床適宜的情況下,可以透過居家給藥和數位化後續觀察提高便利性。這些變化促使人們更加重視替代政策、冷鏈可靠性、病患教育以及腫瘤團隊、藥局和保險公司之間的協作。

透過人工智慧(AI)加強風險評估和業務協作

人工智慧 (AI) 可透過結構化臨床數據、治療方案、實驗室結果、合併症和先前併發症,識別嗜中性白血球低下症減少症高風險患者,從而輔助Pegfilgrastim的使用。預測工具可以幫助確定監測的優先順序,調整劑量以匹配化療週期,並識別需要追蹤的患者。然而,臨床檢驗、模型效能的透明度、資料品質、隱私保護和臨床醫生的監督仍然至關重要。人工智慧應作為指南評估和個人化醫療判斷的補充,而非替代。

區域差異體現在醫療服務取得、基礎設施和照護途徑等。

北美地區擁有完善的腫瘤醫療基礎設施、積極主動的保險公司和處方藥清單管理,以及豐富的長效粒細胞集落刺激因子(G-CSF)使用經驗。歐洲則將成熟的支持治療實務與各國特有的報銷體系、衛生技術評估和生物相似藥政策結合。亞太地區擁有先進的腫瘤醫療體系,但經濟能力、診斷能力和冷鏈供應等方面仍有不平衡。拉丁美洲的特徵是公共和私人醫療服務水準存在差異,且各國之間的醫療服務可近性也存在差異。在中東,專科醫療資源集中在部分市場,而轉診模式和採購結構則影響藥物的供應。非洲在腫瘤醫療基礎設施、實驗室資源、資金籌措和醫療服務的連續性方面存在顯著差異,因此,藥物的可及性和供應可靠性成為至關重要的考量。

經濟和政治集團會影響採購和進入。

在東協地區,由於監管成熟度、報銷系統和醫院容量的差異,實施條件各不相同。金磚國家成員國的公共衛生體系、國內製造業能力和採購重點也呈現多樣性。歐盟雖然受益於通用的法律規範,但在報銷和採購方面仍存在國家差異。七國集團(G7)國家的腫瘤醫療服務普遍成熟,但支付方對法規和臨床指引的解讀仍會影響醫療服務的可近性。海灣合作理事會(GCC)國家通常採用集中採購體系,同時發展快速的專科醫療服務。北約成員國的醫療體系模式多種多樣,因此加入北約並不一定意味著在醫療服務取得、臨床實踐或報銷方面具有統一性。

成熟的醫療衛生體系和發展中醫療衛生體系的優先事項因國家而異。

澳洲和加拿大注重實證報銷、區域可近性和協調一致的癌症治療路徑。巴西、墨西哥、印度和俄羅斯的醫療保健在大都會圈和偏遠地區之間存在顯著差異,治療機會取決於經濟負擔和供應的穩定性。中國正在擴展其癌症治療體系,同時努力平衡集中化政策、國內生產和區域差異。日本和韓國擁有完善的癌症治療體系,對劑量、報銷和臨床方案都極為重視。法國、德國、義大利、西班牙和英國在成熟的歐洲框架內運作,但在國家採購、醫療技術評估和處方實踐方面存在差異。在美國,藥物的可近性受到臨床指引、支付方政策、醫療服務地點以及生物相似藥日益激烈的競爭等因素的影響。

優先考慮循證獲取、可靠供應和以患者為中心的支援。

行業領導者應使Pegfilgrastim的定位與指南中定義的患者風險相符,並向臨床醫生、支付方和患者展示重要的治療效果。提高供應鏈韌性、加強溫度控制流程和管理支援可以減少不必要的供應中斷。各機構應在維持藥物安全監測的同時,建立自身關於生物相似藥使用、替代規則和臨床遵從性的證據體系。與腫瘤醫療服務提供者合作可以加強對給藥時間、不利事件識別和適當追蹤的教育。應在包含檢驗、偏差、網路安全和課責等內容的管治框架內,選擇性地實施數位化工具和人工智慧。

對Pegfilgrastim進行嚴格評估的調查方法

穩健的評估需要整契約儕審查的臨床證據、監管和治療指南、衛生技術評估、報銷政策、採購資訊、藥物安全監測數據以及可靠的公共衛生統計數據。分析應區分已核准的適應症和仿單標示外用藥,並明確區分臨床療效、安全性、可近性和營運的考量。區域間、組間和國家間的比較應考慮癌症負擔、醫療保健資金、生物相似藥監管、化療實踐、檢測能力和數據可用性方面的差異。在解釋研究結果之前,應從多個資訊來源進行交叉檢驗,並明確標註日期,且結果應保持一致。

結論:永續價值取決於綜合支持性護理。

當預防化療嗜中性白血球低下症在臨床上適合時,Pegfilgrastim仍然是重要的支持性治療選擇。其作用受到基於風險的癌症治療、與生物相似藥的競爭、分散式醫療、醫保審查以及數位化協作等因素的影響。永續應用更取決於可靠的供應、循證處方、公平的獲取途徑、患者教育以及數據和人工智慧的負責任使用,而非產品本身的可用性。能夠整合這些要素的領導者可以增強治療的連續性,同時支持更安全、更有效率的癌症治療。

目錄

第1章:序言

第2章:調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章:人工智慧的累積影響,2026年

第7章:Pegfilgrastim市場:依產品類型分類

  • 生物製藥Pegfilgrastim
  • 生物相似藥

第8章:Pegfilgrastim市場:以劑型分類

  • 注射液
  • 凍乾粉
  • 預填充式注射器

第9章:Pegfilgrastim市場:依給藥途徑分類

  • 靜脈
  • 皮下

第10章:Pegfilgrastim市場:依患者群體分類

  • 老年患者
  • 兒童患者

第11章:Pegfilgrastim市場:依應用領域分類

  • 化療引起的嗜中性白血球低下症
  • 骨髓惡性腫瘤
  • 放射線治療引起的嗜中性白血球低下症
  • 固體癌
  • 幹細胞移植

第12章Pegfilgrastim市場:依最終用戶分類

  • 門診手術中心
  • 居家照護環境
  • 醫院和診所

第13章:Pegfilgrastim市場:按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章Pegfilgrastim市場:依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章:Pegfilgrastim市場:按國家分類

  • 美國
  • 德國
  • 中國
  • 英國
  • 印度
  • 日本
  • 俄羅斯
  • 巴西
  • 加拿大
  • 義大利
  • 墨西哥
  • 法國
  • 西班牙
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析,2025年
    • 濃度比(CR)
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析,2025 年
  • 2025年產品系列分析
  • 基準分析,2025 年

第17章:公司簡介

  • Amgen Inc.
  • Apotex Inc.
  • Biocon Biologics Limited
  • CinnaGen Inc.
  • Coherus BioSciences, Inc.
  • CuraTeQ Biologics Pvt. Ltd. by Aurobindo Pharma Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi USA, LLC
  • Gennova Biopharmaceuticals Limited.
  • Intas Pharmaceuticals Ltd.
  • Mundipharma International Limited
  • Mylan NV by Viatris Inc.
  • Pfizer Inc.
  • Qilu Pharmaceutical Co., Ltd.
  • Sandoz Inc. by Novartis AG
  • Stada Arzneimittel AG

第18章 主要專家

Product Code: MRR-EBFCC956B933

The Pegfilgrastim Market is projected to grow by USD 3.99 billion at a CAGR of 5.33% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.77 billion
Estimated Year [2026] USD 2.91 billion
Forecast Year [2032] USD 3.99 billion
CAGR (%) 5.33%

Pegfilgrastim: Executive Summary and Market Context

Pegfilgrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) used to reduce the duration of chemotherapy-induced neutropenia and the incidence of febrile neutropenia in appropriate patients. Its clinical value is linked to less frequent administration than short-acting filgrastim, supporting treatment adherence and reducing injection burden. Use is generally guided by chemotherapy risk, patient characteristics, treatment intent, local guidelines, and reimbursement conditions.

Care Delivery Is Shifting Toward Proactive Neutropenia Prevention

The landscape is moving toward risk-based prevention, standardized supportive-care pathways, and greater attention to treatment continuity. Hospitals and oncology networks increasingly emphasize chemotherapy scheduling, dose intensity, adverse-event monitoring, and timely intervention. Biosimilar availability is also reshaping procurement and formulary decisions, while home administration and digital follow-up can improve convenience when clinically appropriate. These shifts place greater importance on interchangeability policies, cold-chain reliability, patient education, and coordination between oncology teams, pharmacies, and payers.

Artificial Intelligence Strengthens Risk Assessment and Operational Coordination

Artificial intelligence can support pegfilgrastim use by identifying patients at elevated risk of febrile neutropenia from structured clinical data, treatment regimens, laboratory results, comorbidities, and prior complications. Predictive tools may help prioritize monitoring, coordinate administration around chemotherapy cycles, and identify patients needing follow-up. However, clinical validation, transparent model performance, data quality, privacy safeguards, and clinician oversight remain essential. AI should complement-not replace-guideline-based assessment and individualized medical judgment.

Regional Differences Reflect Access, Infrastructure, and Care Pathways

North America is characterized by established oncology infrastructure, active payer and formulary management, and broad experience with long-acting G-CSF. Europe combines mature supportive-care practice with country-specific reimbursement, health-technology assessment, and biosimilar policies. Asia-Pacific includes advanced oncology systems alongside settings where affordability, diagnostic capacity, and cold-chain access remain uneven. Latin America is shaped by public-private delivery differences and access variability across countries. The Middle East shows concentrated specialist capacity in some markets, while referral patterns and procurement structures influence availability. Africa faces pronounced differences in oncology infrastructure, laboratory access, financing, and treatment continuity, making implementation and supply reliability central considerations.

Economic and Political Groupings Shape Procurement and Access

Within ASEAN, differences in regulatory maturity, reimbursement, and hospital capacity create varied adoption conditions. BRICS members reflect diverse public-health systems, domestic manufacturing capabilities, and procurement priorities. The European Union benefits from shared regulatory structures while retaining national differences in reimbursement and purchasing. G7 countries generally have mature oncology services, but payer controls and guideline interpretation still affect utilization. GCC countries often combine centralized procurement with rapidly developing specialist care. NATO members span multiple health-system models, so alliance membership does not imply uniform access, clinical practice, or reimbursement.

Country-Level Priorities Vary Across Established and Developing Systems

Australia and Canada emphasize evidence-based reimbursement, regional access, and coordinated oncology pathways. Brazil, Mexico, India, and Russia face important differences between metropolitan and peripheral care, with affordability and supply continuity influencing treatment access. China is expanding oncology capacity while balancing centralized policy, domestic production, and regional variation. Japan and South Korea have sophisticated cancer-care systems with strong attention to dosing, reimbursement, and clinical protocols. France, Germany, Italy, Spain, and the United Kingdom operate within mature European frameworks, but national procurement, health-technology assessment, and prescribing practices differ. In the United States, utilization is influenced by clinical guidelines, payer policies, site of care, and the growing role of biosimilar competition.

Prioritize Evidence-Based Access, Reliable Delivery, and Patient-Centered Support

Industry leaders should align pegfilgrastim positioning with guideline-defined patient risk and demonstrate outcomes that matter to clinicians, payers, and patients. Strengthening supply-chain resilience, temperature-control processes, and administration support can reduce avoidable interruptions. Organizations should prepare differentiated evidence for biosimilar use, substitution rules, and real-world adherence while maintaining pharmacovigilance. Partnerships with oncology providers can improve education on timing, adverse-event recognition, and appropriate follow-up. Digital tools and AI should be deployed selectively, with governance frameworks that address validation, bias, cybersecurity, and accountability.

Research Methodology for a Rigorous Pegfilgrastim Assessment

A robust assessment should combine peer-reviewed clinical evidence, regulatory and treatment guidelines, health-technology assessments, reimbursement policies, procurement information, pharmacovigilance data, and credible public-health statistics. Analysis should distinguish approved indications from off-label practice and separate clinical efficacy, safety, access, and operational considerations. Regional, group, and country comparisons should account for differences in oncology burden, healthcare financing, biosimilar regulation, chemotherapy practice, laboratory capacity, and data availability. Findings should be triangulated across sources, dated clearly, and tested for consistency before interpretation.

Conclusion: Durable Value Depends on Integrated Supportive Care

Pegfilgrastim remains an important supportive-care option where prevention of chemotherapy-induced neutropenia is clinically appropriate. Its role is being shaped by risk-based oncology practice, biosimilar competition, decentralized care, reimbursement scrutiny, and digital coordination. Sustainable adoption will depend less on product availability alone than on reliable supply, evidence-aligned prescribing, equitable access, patient education, and accountable use of data and AI. Leaders that integrate these elements can strengthen treatment continuity while supporting safer, more efficient cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pegfilgrastim Market, by Product Type

  • 7.1. Introduction
  • 7.2. Biologic Pegfilgrastim
  • 7.3. Biosimilars

8. Pegfilgrastim Market, by Dosage Form

  • 8.1. Introduction
  • 8.2. Injectable Solutions
  • 8.3. Lyophilized Powder
  • 8.4. Pre-filled Syringes

9. Pegfilgrastim Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Subcutaneous

10. Pegfilgrastim Market, by Patient Demographics

  • 10.1. Introduction
  • 10.2. Geriatric Patients
  • 10.3. Pediatric Patients

11. Pegfilgrastim Market, by Application

  • 11.1. Introduction
  • 11.2. Chemotherapy-Induced Neutropenia
  • 11.3. Hematologic Malignancies
  • 11.4. Radiation Therapy-induced Neutropenia
  • 11.5. Solid Tumors
  • 11.6. Stem Cell Transplantation

12. Pegfilgrastim Market, by End-User

  • 12.1. Introduction
  • 12.2. Ambulatory Surgical Centers
  • 12.3. Homecare Settings
  • 12.4. Hospitals & Clinics

13. Pegfilgrastim Market, by Region

  • 13.1. Introduction
  • 13.2. Asia-Pacific
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Europe
  • 13.6. Middle East
  • 13.7. Africa

14. Pegfilgrastim Market, by Group

  • 14.1. Introduction
  • 14.2. ASEAN
  • 14.3. GCC
  • 14.4. European Union
  • 14.5. BRICS
  • 14.6. G7
  • 14.7. NATO

15. Pegfilgrastim Market, by Country

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Germany
  • 15.4. China
  • 15.5. United Kingdom
  • 15.6. India
  • 15.7. Japan
  • 15.8. Russia
  • 15.9. Brazil
  • 15.10. Canada
  • 15.11. Italy
  • 15.12. Mexico
  • 15.13. France
  • 15.14. Spain
  • 15.15. Australia
  • 15.16. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. Market Concentration Analysis, 2025
    • 16.2.1. Concentration Ratio (CR)
    • 16.2.2. Herfindahl Hirschman Index (HHI)
  • 16.3. Recent Developments & Impact Analysis, 2025
  • 16.4. Product Portfolio Analysis, 2025
  • 16.5. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Amgen Inc.
  • 17.2. Apotex Inc.
  • 17.3. Biocon Biologics Limited
  • 17.4. CinnaGen Inc.
  • 17.5. Coherus BioSciences, Inc.
  • 17.6. CuraTeQ Biologics Pvt. Ltd. by Aurobindo Pharma Ltd.
  • 17.7. Dr. Reddy's Laboratories Ltd.
  • 17.8. Fresenius Kabi USA, LLC
  • 17.9. Gennova Biopharmaceuticals Limited.
  • 17.10. Intas Pharmaceuticals Ltd.
  • 17.11. Mundipharma International Limited
  • 17.12. Mylan N.V. by Viatris Inc.
  • 17.13. Pfizer Inc.
  • 17.14. Qilu Pharmaceutical Co., Ltd.
  • 17.15. Sandoz Inc. by Novartis AG
  • 17.16. Stada Arzneimittel AG

18. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Pegfilgrastim Market, Years Considered for the Study
  • FIGURE 2. Global Pegfilgrastim Market, Research Design
  • FIGURE 3. Global Pegfilgrastim Market, Research Framework
  • FIGURE 4. Global Pegfilgrastim Market, Data Triangulation
  • FIGURE 5. Global Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Pegfilgrastim Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Pegfilgrastim Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Pegfilgrastim Market Size, by Dosage Form, 2025 vs 2032 (%)
  • FIGURE 9. Global Pegfilgrastim Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Pegfilgrastim Market Size, by Route of Administration, 2025 vs 2032 (%)
  • FIGURE 11. Global Pegfilgrastim Market Size, by Route of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Pegfilgrastim Market Size, by Patient Demographics, 2025 vs 2032 (%)
  • FIGURE 13. Global Pegfilgrastim Market Size, by Patient Demographics, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Pegfilgrastim Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 15. Global Pegfilgrastim Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Pegfilgrastim Market Size, by End-User, 2025 vs 2032 (%)
  • FIGURE 17. Global Pegfilgrastim Market Size, by End-User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Pegfilgrastim Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 19. Global Pegfilgrastim Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Pegfilgrastim Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Pegfilgrastim Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 22. Global Pegfilgrastim Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Pegfilgrastim Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Pegfilgrastim Market Segmentation & Coverage
  • TABLE 2. Global Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Biologic Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Biologic Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Biologic Pegfilgrastim Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Biosimilars Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Biosimilars Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Biosimilars Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 11. Global Injectable Solutions Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 12. Global Injectable Solutions Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 13. Global Injectable Solutions Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 14. Global Lyophilized Powder Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Lyophilized Powder Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Lyophilized Powder Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Pre-filled Syringes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Pre-filled Syringes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Pre-filled Syringes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 21. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 22. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 23. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 24. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 28. Global Geriatric Patients Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Geriatric Patients Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Geriatric Patients Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Pediatric Patients Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Pediatric Patients Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Pediatric Patients Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 35. Global Chemotherapy-Induced Neutropenia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Chemotherapy-Induced Neutropenia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Chemotherapy-Induced Neutropenia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Hematologic Malignancies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Hematologic Malignancies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Hematologic Malignancies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Radiation Therapy-induced Neutropenia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Radiation Therapy-induced Neutropenia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Radiation Therapy-induced Neutropenia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Stem Cell Transplantation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Stem Cell Transplantation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Stem Cell Transplantation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 51. Global Ambulatory Surgical Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Ambulatory Surgical Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Ambulatory Surgical Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Homecare Settings Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Global Homecare Settings Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 56. Global Homecare Settings Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 57. Global Hospitals & Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Global Hospitals & Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 59. Global Hospitals & Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 60. Global Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Asia-Pacific Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Asia-Pacific Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 63. Asia-Pacific Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 64. Asia-Pacific Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 65. Asia-Pacific Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 66. Asia-Pacific Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 67. Asia-Pacific Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 68. North America Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. North America Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 70. North America Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 71. North America Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 72. North America Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 73. North America Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 74. North America Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 75. Latin America Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Latin America Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 77. Latin America Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 78. Latin America Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 79. Latin America Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 80. Latin America Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 81. Latin America Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 82. Europe Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 83. Europe Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 84. Europe Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 85. Europe Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 86. Europe Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 87. Europe Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 88. Europe Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 89. Middle East Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Middle East Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 91. Middle East Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 92. Middle East Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 93. Middle East Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 94. Middle East Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 95. Middle East Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 96. Africa Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 97. Africa Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 98. Africa Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 99. Africa Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 100. Africa Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 101. Africa Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 102. Africa Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 103. Global Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 104. ASEAN Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 105. ASEAN Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 106. ASEAN Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 107. ASEAN Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 108. ASEAN Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 109. ASEAN Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 110. ASEAN Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 111. GCC Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 112. GCC Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 113. GCC Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 114. GCC Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 115. GCC Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 116. GCC Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 117. GCC Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 118. European Union Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 119. European Union Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 120. European Union Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 121. European Union Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 122. European Union Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 123. European Union Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 124. European Union Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 125. BRICS Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 126. BRICS Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 127. BRICS Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 128. BRICS Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 129. BRICS Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 130. BRICS Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 131. BRICS Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 132. G7 Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 133. G7 Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 134. G7 Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 135. G7 Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 136. G7 Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 137. G7 Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 138. G7 Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 139. NATO Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 140. NATO Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 141. NATO Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 142. NATO Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 143. NATO Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 144. NATO Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 145. NATO Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 146. Global Pegfilgrastim Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 147. United States Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 148. United States Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 149. United States Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 150. United States Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 151. United States Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 152. United States Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 153. United States Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 154. Germany Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 155. Germany Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 156. Germany Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 157. Germany Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 158. Germany Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 159. Germany Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 160. Germany Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 161. China Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 162. China Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 163. China Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 164. China Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 165. China Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 166. China Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 167. China Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 168. United Kingdom Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 169. United Kingdom Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 170. United Kingdom Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 171. United Kingdom Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 172. United Kingdom Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 173. United Kingdom Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 174. United Kingdom Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 175. India Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 176. India Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 177. India Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 178. India Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 179. India Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 180. India Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 181. India Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 182. Japan Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 183. Japan Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 184. Japan Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 185. Japan Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 186. Japan Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 187. Japan Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 188. Japan Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 189. Russia Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 190. Russia Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 191. Russia Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 192. Russia Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 193. Russia Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 194. Russia Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 195. Russia Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 196. Brazil Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 197. Brazil Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 198. Brazil Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 199. Brazil Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 200. Brazil Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 201. Brazil Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 202. Brazil Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 203. Canada Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 204. Canada Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 205. Canada Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 206. Canada Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 207. Canada Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 208. Canada Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 209. Canada Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 210. Italy Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 211. Italy Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 212. Italy Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 213. Italy Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 214. Italy Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 215. Italy Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 216. Italy Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 217. Mexico Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 218. Mexico Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 219. Mexico Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 220. Mexico Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 221. Mexico Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 222. Mexico Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 223. Mexico Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 224. France Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 225. France Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 226. France Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 227. France Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 228. France Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 229. France Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 230. France Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 231. Spain Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 232. Spain Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 233. Spain Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 234. Spain Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 235. Spain Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 236. Spain Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 237. Spain Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 238. Australia Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 239. Australia Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 240. Australia Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 241. Australia Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 242. Australia Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 243. Australia Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 244. Australia Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 245. South Korea Pegfilgrastim Market Size, 2017-2032 (USD Million)
  • TABLE 246. South Korea Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 247. South Korea Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 248. South Korea Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 249. South Korea Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
  • TABLE 250. South Korea Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 251. South Korea Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 252. Global Pegfilgrastim Market Share, by Key Player, 2025
  • TABLE 253. Global Pegfilgrastim Market, Key Experts